"Hematologic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that act on blood and blood-forming organs and those that affect the hemostatic system.
Descriptor ID |
D006401
|
MeSH Number(s) |
D27.505.954.502
|
Concept/Terms |
Hematologic Agents- Hematologic Agents
- Agents, Hematologic
- Hematological Agents
- Agents, Hematological
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Agents".
This graph shows the total number of publications written about "Hematologic Agents" by people in this website by year, and whether "Hematologic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 3 | 1 | 4 |
2018 | 1 | 2 | 3 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Agents" by people in Profiles.
-
Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):71-78.
-
Post-COVID-19 severe neutropenia. Pediatr Blood Cancer. 2021 05; 68(5):e28866.
-
Current Overview on Hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020 Oct; 20(5):393-403.
-
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. Transfusion. 2020 12; 60(12):3066-3067.
-
COVID-19 in a pediatric patient with Glanzmann thrombasthenia. Pediatr Blood Cancer. 2020 10; 67(10):e28662.
-
Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. Eur J Intern Med. 2019 Jul; 65:4-5.
-
Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med. 2018 09 19; 16(1):158.
-
Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med. 2018 Jun 07; 378(23):2182-2190.
-
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. J Am Coll Cardiol. 2018 03 20; 71(11):1231-1242.
-
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 01; 26(1):7-20.